Biopharmaceutical company focused on dermatological and immuno-inflammatory diseases.
Aclaris Therapeutics, Inc., headquartered in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company specializing in the development of innovative drug candidates aimed at treating immune-inflammatory diseases across the United States. The company operates through two distinct segments: Therapeutics and Contract Research. The Therapeutics segment focuses on identifying and advancing novel therapies to address significant unmet medical needs in immuno-inflammatory conditions.
Aclaris Therapeutics' robust pipeline includes several promising candidates. Among these are Zunsemetinib, an MK2 inhibitor targeting moderate to severe rheumatoid and psoriatic arthritis, as well as hidradenitis suppurativa. Another notable development is ATI-1777, a selective JAK 1/3 inhibitor designed for the treatment of moderate to severe atopic dermatitis, addressing critical needs in dermatological care.
Additionally, the company is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor with potential applications in T cell-mediated autoimmune diseases. Aclaris Therapeutics is also engaged in a Gut-Biased Program targeting inflammatory bowel disease, and is developing ATI-2231, an oral MK2 inhibitor intended for treating pancreatic and metastatic breast cancer.
Founded in 2012, Aclaris Therapeutics has established itself as a leader in the biopharmaceutical sector, driven by a commitment to scientific innovation and patient-centered research. With a strategic focus on advancing transformative therapies, the company continues to expand its portfolio and explore new avenues in addressing complex medical challenges globally.